14 Day Repeat Dose Toxicity Study in Rats
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $700,000 to $1,500,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
-
- Catherine Bigger catherine.bigger@nih.gov
- Miranda Adams miranda.adams@nih.gov (240) 669-5344
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health (NIH) forecasts a new requirement for a 14 Day Repeat Dose Toxicity Study in Rats, with an estimated solicitation release date of June 1, 2026 and an estimated award date of July 1, 2026. The work is a Preclinical Services (PCS) Request for Task Order supporting the IND filing for BioVinc's BV63072, which combines a bone-targeting bisphosphonic acid with sitafloxacin to deliver the antibiotic directly to sites of bone infection in osteomyelitis caused by S. aureus. BioVinc has completed non-GLP PK and safety studies in rats and pilot studies in sheep, and the task order covers IND-enabling studies in two species.
The estimated award value range is $700,000 to $1.5 million, with no set-aside used. Contracting Officer Miranda Adams (miranda.adams@nih.gov, +12406695344) and Catherine Bigger (catherine.bigger@nih.gov) are the NIH points of contact.
Forecast text
This is a Preclinical Services (PCS) Request for Task Order release to support IND filing for BioVinc's BV63072, which combines a bone targeting bisphosphonic acid (BP) with sitafloxacin to allow direct delivery of the antibiotic to sites of bone infection. Osteomyelitis infections caused by S. aureus remain difficult infections to treat with standard of care antibiotics such as sitafloxacin and vancomycin alone. BV63072 has demonstrated improved outcomes in animal models of osteomyelitis compared to vancomycin and sitafloxacin alone and also demonstrated reduced toxicity due to lower systemic exposure of the animals to sitafloxacin. BioVinc has completed non-GLP PK and safety studies in rats and pilot studies in sheep and are now ready to complete IND enabling studies in 2 species.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast